跳转到主要内容


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
快速连接

Lurbinectedin

Lurbinectedin API

Lurbinectedin-API

CAS Number: 497871-47-3

治疗类别
抗癌/抗肿瘤
API技术
合成
剂型
Intravenous
瑞迪博士研发状态
正在开发中
创新品牌(美国)
Zepzelca
Plant
EMQA

作用机制

Lurbinectedin is an antineoplastic agent that belongs to the class of drugs called alkylating agents. It works by inducing DNA damage and blocking DNA repair, leading to cell death in cancer cells.

The mechanism of action of lurbinectedin involves the binding of the drug to DNA and the formation of covalent bonds with the DNA molecule. This binding leads to the formation of DNA adducts, which interfere with the normal functioning of DNA, including DNA replication and transcription.

Lurbinectedin specifically targets a type of RNA transcription called ""RNA polymerase II termination factor (RTF)"" which is overproduced in certain cancer cells. By inhibiting RTF, lurbinectedin causes the accumulation of RNA polymerase II on the DNA, leading to DNA damage and the eventual death of the cancer cell.

适应症

Lurbinectedin is a chemotherapy drug that is indicated for the treatment of advanced small cell lung cancer (SCLC) in adult patients with disease progression on or after platinum-based chemotherapy. It is also indicated for the treatment of adult patients with relapsed and refractory small cell lung cancer (RR-SCLC) who have received at least two prior lines of therapy.

It works by binding to and inhibiting the activity of an enzyme called RNA polymerase, which is important for the replication of cancer cells. This leads to the death of cancer cells and slows the progression of the disease.

Lurbinectedin should be administered under the supervision of a qualified healthcare provider experienced in the administration of cancer chemotherapy. It is important to carefully follow the dosing and administration instructions provided by your healthcare provider.

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴,是全球领先的活性药物成分(API)供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API(如类固醇,多肽,复杂长链分子和高效API(HPAPI /肿瘤药物))方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准,从而为这一专业知识提供补充。 Dr. Reddy's博士 Lurbinectedin API是研发,知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量,安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化,从而避免短缺并满足需求的突然激增。

Oncology API Products:

Learn More

联系我们

请填写以下表格,我们会尽快与您联系

给我们发电子邮件: api@drreddys.com | +91 40 49002222

如果您有任何特定于国家的要求,我们将为您提供帮助。

免责声明

本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。